about
Micronutrient Antioxidants and Nonalcoholic Fatty Liver DiseaseThe Role of Chemokines in Shaping the Balance Between CD4(+) T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer DiseasesRoles of Chemokines and Chemokine Receptors in Obesity-Associated Insulin Resistance and Nonalcoholic Fatty Liver DiseaseCXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systemsNeoplastic "Black Ops": cancer's subversive tactics in overcoming host defensesChemokine receptors and their therapeutic opportunities in diseased lung: far beyond leukocyte traffickingNaturally occurring anthraquinones: chemistry and therapeutic potential in autoimmune diabetesStructural Basis of Chemokine Sequestration by a Tick Chemokine Binding Protein: The Crystal Structure of the Complex between Evasin-1 and CCL3Expression of chemokines and their receptors in human and simian astrocytes: evidence for a central role of TNF alpha and IFN gamma in CXCR4 and CCR5 modulationPulmonary fibrosis: pathogenesis, etiology and regulationCCR7 ligand-enhanced phagocytosis of various antigens in mature dendritic cells-time course and antigen distribution different from phagocytosis in immature dendritic cellsTherapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice.Ccl22/MDC, is a prostaglandin dependent pyrogen, acting in the anterior hypothalamus to induce hyperthermia via activation of brown adipose tissue.CXCL9-Derived Peptides Differentially Inhibit Neutrophil Migration In Vivo through Interference with Glycosaminoglycan InteractionsChemokine-glycosaminoglycan binding: specificity for CCR2 ligand binding to highly sulfated oligosaccharides using FTICR mass spectrometry.Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.Dose-response met-RANTES treatment of experimental periodontitis: a narrow edge between the disease severity attenuation and infection control.The chemokine receptor CCR1 is strongly up-regulated after skin injury but dispensable for wound healing.Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungsTherapeutic efficacy and immunological response of CCL5 antagonists in models of contact skin reactionRecombinant herpesvirus glycoprotein G improves the protective immune response to Helicobacter pylori vaccination in a mouse model of disease.Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinomaC-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis.Isorhynchophylline, a Potent Plant Alkaloid, Induces Apoptotic and Anti-Metastatic Effects in Human Hepatocellular Carcinoma Cells through the Modulation of Diverse Cell Signaling Cascades.α-Mangostin ameliorates hepatic steatosis and insulin resistance by inhibition C-C chemokine receptor 2CC chemokine receptor 4 modulates Toll-like receptor 9-mediated innate immunity and signaling.Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis.Association of serum interleukin-27 with the exacerbation of chronic obstructive pulmonary diseaseCXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1.Macrophages recruited via CCR2 produce insulin-like growth factor-1 to repair acute skeletal muscle injury.Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancerFragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.Met-CCL5 represents an immunotherapy strategy to ameliorate rabies virus infection.Morus alba and active compound oxyresveratrol exert anti-inflammatory activity via inhibition of leukocyte migration involving MEK/ERK signalingEmodin suppresses migration and invasion through the modulation of CXCR4 expression in an orthotopic model of human hepatocellular carcinomaGlycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokinesInvolvement of the nuclear factor-κB signaling pathway in the regulation of CXC chemokine receptor-4 expression in neuroblastoma cells induced by tumor necrosis factor-α.The chemokine SDF-1/CXCL12 modulates the firing pattern of vasopressin neurons and counteracts induced vasopressin release through CXCR4.Novel therapies for the treatment of inflammatory airway disease.Lead identification and structure-activity relationships of heteroarylpyrazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
P2860
Q26738646-04154ACA-EEA2-4D4C-B872-6F91C656BE1DQ26773127-844EE7E9-C093-4292-BA0A-0C87E9538ACBQ26801371-2647EFC1-3986-42AE-907C-66BF4163D6ECQ26992010-3D886AA8-5B98-42A6-ACA8-771794B493CDQ27001081-CE1DC361-D41E-4FE6-AA5C-8CF015BEECAAQ27013008-558A4BA4-454D-4016-A81F-2151D59B030FQ27022572-A6DC46CF-7B3E-45EF-BA1A-A974DA38EA7BQ27658814-41D60B3E-D688-40CC-AA4C-097604AEB04CQ28205775-3B09A613-80CA-4727-99B8-CB024FFC37F7Q28388425-69F6FC1F-4F62-4743-A239-6E7DF0BC6443Q28592208-0C19F504-231E-4CDA-8E74-E79CF4731F2CQ30438279-8E00E49A-B0BA-476B-AD6D-97BD7D03CF9DQ30498100-43E440BC-B9E6-4EAE-9B32-5C94C2513F1DQ30848125-62CE8200-B384-4D0D-8463-5FFF6461CA3FQ30857874-BCBA4A5E-A91B-4E99-B7A1-15D304DFE573Q31020601-B98803AC-3BFE-4533-A140-C59454BC21F9Q31028208-BEED3054-7029-4C97-BEE9-C86EF4901E89Q33201642-B6003AA2-D6CB-4381-A1B7-4E5DBB73CF84Q33315753-22B41528-AB8D-4467-A377-8758FBEB4D6FQ33525579-E9B44ACF-0D0A-418A-8B66-BCF3F96BEDC1Q33560566-1105943C-B74F-4B07-BF70-4A85F7552A4DQ33728994-C3A9A3CA-1934-4D0B-9337-2323223A65C4Q33750735-D49FCBE5-2C57-4051-BDD9-873B25107258Q33755460-4390FBD4-79D2-435D-B408-3F4D5A4681D6Q33783727-8A2409FD-497E-4ADB-BDCB-7A6BC0F22224Q34078439-A30D3946-4CED-4B39-BFCA-52D549D1BD22Q34141587-533B298B-D409-4837-8AB8-1E7927C076C9Q34297424-17A549F2-6192-49BA-B338-ED1C9046F9FCQ34299243-F8C11B82-E09B-437B-A318-018DCABA5B4AQ34421842-6600420A-6B5A-4060-8923-A50C58E7B4AAQ34452046-F9FAF2E9-E96C-4881-A962-10C2BEAA619FQ34569177-1FADB336-6E6D-4BAE-A465-BF920F8836F5Q34571301-E3FC6C1D-8260-4B57-817D-D779925CC2BCQ34596234-58F3147F-5F80-4053-990F-95EE8F4658DBQ34614290-4CA51F51-9ADE-496E-9417-8B2805C374CCQ34762409-BB92F841-6A67-4873-8545-3028F80B6198Q34936465-C8C6C853-5B31-4A79-850F-56130BCC3103Q35039347-62F64BC0-2937-4245-8FF7-E851CF5C6BB2Q35040779-9CCEA703-55DB-41CF-AE16-7E0F7D305FC1Q35090956-700A0328-65B4-465A-BE08-AF56B7E1EB18
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Chemokine receptors: multifaceted therapeutic targets.
@ast
Chemokine receptors: multifaceted therapeutic targets.
@en
Chemokine receptors: multifaceted therapeutic targets.
@nl
type
label
Chemokine receptors: multifaceted therapeutic targets.
@ast
Chemokine receptors: multifaceted therapeutic targets.
@en
Chemokine receptors: multifaceted therapeutic targets.
@nl
prefLabel
Chemokine receptors: multifaceted therapeutic targets.
@ast
Chemokine receptors: multifaceted therapeutic targets.
@en
Chemokine receptors: multifaceted therapeutic targets.
@nl
P921
P356
P1476
Chemokine receptors: multifaceted therapeutic targets.
@en
P2093
Amanda E I Proudfoot
P304
P356
10.1038/NRI722
P577
2002-02-01T00:00:00Z